Vanderbilt University Medical Center: Study Reveals Need for Matching Targeted Therapies With EGFR Subtypes
July 29, 2022
July 29, 2022
NASHVILLE, Tennessee, July 29 (TNSres) -- Vanderbilt University Medical Center issued the following news:
By Tom Wilemon
New research from Vanderbilt investigators suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
EGFR exon 19 deletion mutations are the most common EGFR mutations in patients with lung cancer. However, the term "exon 19 deletion" . . .
By Tom Wilemon
New research from Vanderbilt investigators suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
EGFR exon 19 deletion mutations are the most common EGFR mutations in patients with lung cancer. However, the term "exon 19 deletion" . . .